Emgality ® ▼ (galcanezumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

Can a patient be vaccinated during Emgality® ▼ (galcanezumab) treatment?

The concomitant use of galcanezumab and vaccinations has not been studied, but it is not contraindicated. Galcanezumab is not anticipated to interact with the host immune system, nor have any drug interactions.


Concomitant Vaccine Use in Galcanezumab Clinical Trial

Eli Lilly and Company have not evaluated the safety and efficacy of galcanezumab in combination with vaccines.

The use of vaccines with galcanezumab is not contraindicated.1

Based on the mechanism of action, the mechanism of elimination, and the characteristics of galcanezumab, there is no reason to expect an interaction

  • with the host immune system or
  • with galcanezumab and other drugs. 1

The decision to administer a vaccination to a patient before, during, or after galcanezumab treatment must be based on the clinical judgment of the prescribing healthcare practitioner after careful consideration of the patient's risk factors as well as the risks and benefits of vaccination.

Please follow local guidance regarding vaccine schedules and recommendations. 

In the phase 3 clinical studies, patients received vaccines during double-blind, placebo-controlled, and open-label galcanezumab treatment; however, subgroup analyses were not completed in this population.1

Vaccines Administered During Phase 3 Migraine Prevention Clinical Trials

Vaccine usage was low overall in the phase 3 migraine prevention studies.1 The influenza vaccine was the most commonly administered vaccine during galcanezumab treatment, with reported usage in 1.26% to 2.82% of patients receiving galcanezumab.

Other vaccines administered to at least 1 galcanezumab-treated patient included

  • anthrax
  • hepatitis
  • human papilloma
  • meningococcal
  • pneumococcal
  • tetanus
  • tick-borne encephalitis, and
  • varicella zoster.1

Subgroup analyses were not completed in this population.


1Data on file, Eli Lilly and Company and/or one of its subsidiaries.


CGRP = calcitonin gene-related peptide

IgG4 = immunoglobulin G (subclass) 4

mAb = monoclonal antibody

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: 19 July 2021

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request